Inivata Highlights New Clinical Data on InVision(TM) ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017
First data published using amplicon-based technology to detect ALK and ROS1 fusions
Highly sensitive detection of resistance mutations provides basis for optimising
therapy for patients with relapsed NSCLC
Research Triangle Park, NC and Cambridge, UK, 17 October, 2017 -- Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces that new clinical data from its collaboration with the Dana-Farber Cancer Institute will be presented at the World Conference on Lung Cancer (WCLC).
The study involved a blind retrospective evaluation of Inivata's InVision ctDNA liquid biopsy analysis to characterize and monitor the molecular profile of advanced non-small cell lung cancer (NSCLC) during genotype-directed therapy with osimertinib.
Inivata's technology was shown to detect a full range of genotypes, including gene rearrangements, with an exquisite sensitivity and a high specificity. It was able to detect ALK and ROS1 fusions with high sensitivity, the first time this has been shown using amplicon sequencing. As published previously, there was excellent concordance with droplet digital PCR (ddPCR).
The data will be presented by first author Dr. Nicolas Guibert at 09:30 on Wednesday 18 October in the Biology/ Pathology Poster Session in Exhibit Hall B+C.
Poster (P3.02-014): Amplicon-based next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA) for detection of driver and resistance mutations in advanced NSCLC.
Commenting on the data, Geoffrey Oxnard, MD, thoracic oncologist and lung cancer researcher at Dana-Farber Cancer Institute, said, "These data show InVision is able to accurately deliver actionable information to clinicians about a range of genetic alterations and, in particular, its potential to inform the treatment of drug resistance. We look forward to further exploring this assay and its potential to impact patient outcomes."
Clive Morris, Chief Medical Officer of Inivata, said, "This is the first time an amplicon based approach to next generation sequencing has been able to detect a full range of targetable genotypes in NSCLC, including ALK and ROS1 fusions. The study also provided further evidence of our platform's exceptional sensitivity. The breadth of our panel and the sensitivity of InVision is a powerful combination and we continue to add to the body of evidence supporting its clinical utility."
About Inivata
Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care. Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision(TM) liquid biopsy platform, based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with a select multi-gene panel to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies. The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
About the WCLC
The World Conference on Lung Cancer (WCLC) is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting over 6,000 researchers, physicians and specialists from more than 100 countries. The goal is to disseminate the latest scientific achievements; increase awareness, collaboration and understanding of lung cancer; and to help participants implement the latest developments across the globe. Organized under the theme of "Synergy to Conquer Lung Cancer," the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit http://wclc2017.iaslc.org/.
Media Contacts:
Consilium Strategic Communications
Chris Gardner/Laura Thornton/ Rosie Phillips
inivata@consilium-comms.com
+44 (0)20 3709 5700
Inivata
Karen Chandler-Smith
karen.chandler-smith@inivata.com
+44 (0)7900 430235